Sosei Group Corporation

08/05/2022 | Press release | Distributed by Public on 08/04/2022 19:44

Sosei Heptares’ Oral, Selective M4 Receptor Agonist Advancing into Phase 2 Clinical Development under Multi-Program Collaboration with Neurocrine